Loading
A phase 2 trial of osimertinib, carboplatin and pemetrexed in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers is a phase 2, randomised interventional study registered as NCT04410796 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 571 participants, started 2020-05-28 and due to reach its primary completion in 2027-05. Interventions recorded: Osimertinib; Carboplatin; Pemetrexed. Conditions listed: Metastatic Non-small Cell Lung Cancer. Primary outcome: Determine the progression-free survival. Lung eligibility wording from the registry: "* Biopsy proven metastatic non-small cell lung cancer, confirmed at enrolling institution". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.